DMAA Targeted In N.Y. Ban Effort, USP Labs Settles
This article was originally published in The Tan Sheet
Executive Summary
A New York lawmaker moves to ban DMAA sales in the state, and USP Labs sets aside $2 million to settle class action suit over the product. FDA continues to work with firms that received related warning letters.